ClinicaliQ Trial Snapshot
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — Recruiting • Phase II • Oncology • NCT07069712.
- What is being tested: Novel agents or novel combination therapies administered perioperatively (before and after surgery) in patients with locally advanced resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma, evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity.
- Patient eligibility overview: Treatment-Phase IIïve adults with locally advanced resectable gastroesophageal adenocarcinoma (gastric, GEJ, or esophageal origin) who are candidates for surgical resection and have not previously received systemic therapy for their disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Eligibility Snapshot
- : * Histologically documented gastric, GEJ, or esophageal adenocarcinoma with resectable disease * Participants who are CLDN18.2-positive and HER2-negative in Sub-study 1 or HER2-positive in Sub-study 2; no specific requirements for Sub-study 3 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ and bone marrow function * Body weight > 35 kg
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.